NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, REGN stock has increased by 6.2% and is now trading at $493.32. View which stocks have been mosted impacted by Coronavirus.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) posted its earnings results on Thursday, February, 6th. The biopharmaceutical company reported $7.50 earnings per share for the quarter, beating analysts' consensus estimates of $6.03 by $1.47. The biopharmaceutical company had revenue of $2.17 billion for the quarter, compared to analyst estimates of $2.10 billion. Regeneron Pharmaceuticals had a net margin of 26.91% and a return on equity of 24.14%. The company's revenue was up 12.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.84 earnings per share. View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals announced that its Board of Directors has approved a stock repurchase program on Tuesday, November 5th 2019, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 2.9% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.

24 analysts have issued 12-month price objectives for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $550.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $459.92 in the next year. This suggests that the stock has a possible downside of 6.8%. View analysts' price targets for Regeneron Pharmaceuticals.

News articles about REGN stock have been trending very negative recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutRegeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 2,558,900 shares, a drop of 11.1% from the February 27th total of 2,880,000 shares. Based on an average daily volume of 1,294,900 shares, the days-to-cover ratio is presently 2.0 days. Approximately 3.1% of the shares of the company are sold short. View Regeneron Pharmaceuticals' Current Options Chain.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Repligen (RGEN) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Biogen (BIIB), Celgene (CELG), Tesla (TSLA), Alphabet (GOOG), Micron Technology (MU) and Broadcom (AVGO).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Christopher R Fenimore, George L Sing, Joseph J Larosa, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was purchased by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC. View insider buying and selling activity for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $493.32.

Regeneron Pharmaceuticals has a market capitalization of $54.28 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe. View additional information about Regeneron Pharmaceuticals.

The official website for Regeneron Pharmaceuticals is http://www.regeneron.com/.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]